Antipsychotic Drugs

Most antipsychotics are extensively metabolized by hepatic cytochrome P450 enzymes and are therefore subject to clinically meaningful pharmacokinetic changes in hepatic impairment. Reduced hepatic blood flow and decreased cytochrome P450 enzyme activity in cirrhosis prolong half-lives and increase peak plasma concentrations by reducing first-pass metabolism. Olanzapine, quetiapine, clozapine, aripiprazole, and risperidone all require dose reduction or slower titration in moderate to severe hepatic impairment.

Paliperidone is the important exception: because it is renally cleared with minimal hepatic metabolism, its dosing is largely unaffected by hepatic impairment and it may be preferred in patients with significant liver disease. Haloperidol and other first-generation antipsychotics are similarly subject to impaired clearance in liver disease, with increased extrapyramidal symptom risk at standard doses due to elevated plasma levels.

Most antipsychotics undergo negligible renal clearance of the parent drug and are relatively unaffected by reduced kidney function. Paliperidone is the principal exception — approximately 59 percent is excreted unchanged in the urine, requiring dose reduction when creatinine clearance falls below 80 milliliters per minute, with substantial reductions at lower clearance rates. The active metabolite of risperidone (paliperidone) also accumulates in renal insufficiency, warranting risperidone dose reduction proportional to the degree of renal function decline.

Elderly patients require systematically lower antipsychotic doses for several converging reasons: reduced hepatic cytochrome P450 enzyme activity prolongs half-lives; reduced renal clearance accumulates renally excreted metabolites; decreased plasma protein binding increases the free fraction of highly protein-bound agents; and reduced baseline nigrostriatal dopamine reserve substantially lowers the threshold for drug-induced parkinsonism. Pharmacodynamic sensitivity to anticholinergic effects (cognitive impairment, urinary retention), orthostatic hypotension (fall and fracture risk), and QTc prolongation is also substantially increased in elderly patients compared with younger adults.

As a practical consequence, dose initiation in elderly patients should begin at 25 to 50 percent of the standard adult starting dose with slower titration. Quetiapine at low doses is commonly chosen in elderly patients for its negligible extrapyramidal symptom and drug-induced parkinsonism risk. Clozapine, while highly effective for treatment-resistant conditions, carries disproportionate risks in the elderly due to orthostatic hypotension, sedation, and cognitive impairment from its anticholinergic and histamine H1 blocking properties.

All antipsychotics carry a Food and Drug Administration black-box warning for increased mortality in elderly patients with dementia-related psychosis. Meta-analyses demonstrated an approximately 1.6 to 1.7-fold increase in all-cause mortality — predominantly cardiovascular and infectious causes — compared with placebo in this population. This warning applies to both first-generation and second-generation antipsychotics.

The appropriate clinical response is not categorically refusing to use antipsychotics in dementia but to use them only after non-pharmacological interventions have been exhausted, at the lowest effective dose, for the shortest duration necessary, with documented informed consent from the patient or surrogate, and with regular reassessment of ongoing need. Quetiapine is most commonly used in this context, primarily because of its tolerability profile despite limited evidence for efficacy in behavioral and psychological symptoms of dementia.

The most widely used operational definition requires failure of at least two antipsychotics from different chemical classes at doses equivalent to at least 600 milligrams per day of chlorpromazine equivalents for at least 6 weeks each, with confirmed medication adherence. The requirement for confirmed adherence is essential — apparent treatment resistance due to non-adherence is common and must be excluded before the treatment-resistant schizophrenia label is applied. Plasma level monitoring, pill counts, and long-acting injectable formulations are all tools for confirming adherence.

Clozapine produces meaningful clinical response in approximately 30 to 60 percent of confirmed treatment-resistant schizophrenia patients — compared with near-zero response rates to further trials of standard antipsychotics in this population. No other agent, strategy, or augmentation has been shown to match clozapine's response rates. Clozapine should be initiated after the second antipsychotic trial failure, not as a last resort after exhausting every other available option. Current evidence consistently shows that the median delay from treatment-resistant schizophrenia criteria being met to clozapine initiation is 4 to 9 years in real-world practice — representing years of unnecessary positive symptom burden, progressive functional decline, and preventable suicide risk.

Plasma clozapine level monitoring, with a target of 350 to 600 nanograms per milliliter, is recommended to confirm therapeutic exposure before declaring clozapine failure. Apparent non-response at a plasma level below 350 nanograms per milliliter represents inadequate dosing rather than true clozapine resistance.

When clozapine at therapeutic plasma levels produces partial but incomplete response, augmentation strategies are employed. The most studied augmentation is adding a second antipsychotic — most commonly amisulpride or aripiprazole — to clozapine. Aripiprazole augmentation of clozapine produces metabolic benefits (weight reduction, improved glucose and lipid profiles) and may provide modest additional antipsychotic effect. Lamotrigine augmentation has some randomized trial evidence for improvement in negative and cognitive symptoms in partial clozapine responders, though effects are modest. Valproate is frequently added for seizure prophylaxis at doses above 600 milligrams per day and for mood stabilization in schizoaffective disorder — carbamazepine remains contraindicated.

A subset of patients fails to respond adequately even to therapeutic clozapine — sometimes termed ultra-treatment-resistant schizophrenia. Electroconvulsive therapy combined with clozapine has the most evidence in this population, with several case series and small trials demonstrating clinically meaningful improvement in patients who had not responded to clozapine alone.

Negative symptoms may be primary — arising from the intrinsic pathophysiology of schizophrenia and reflecting mesocortical dopamine deficiency — or secondary to treatable causes: extrapyramidal side effects producing akinesia and flattened affect, depression, inadequately treated positive symptoms driving social withdrawal, or excessive sedation from medication. The first clinical step in addressing prominent negative symptoms is to exclude secondary causes, because treating extrapyramidal side effects, depression, or medication overload is more effective than adding a negative symptom-targeted pharmacological agent to an unchanged regimen.

For primary negative symptoms, cariprazine has the strongest pharmacological evidence base, supported by the Nemeth et al. 2017 Lancet trial demonstrating superiority over risperidone in a 26-week randomized controlled trial specifically powered for a primary negative symptom endpoint — the only trial of this design for any pharmacological intervention. Lurasidone shows secondary benefits on negative symptom scales, likely through its serotonin 5-HT7 antagonism promoting prefrontal cortex dopamine tone. No other approved antipsychotic has this level of evidence for a primary negative symptom endpoint.

Rapid tranquilization refers to the pharmacological management of acute agitation in the context of psychotic illness, aiming for sufficient behavioral calming to ensure safety without excessive sedation that prevents clinical assessment or creates respiratory risk. The approach follows a structured sequence.

First, attempt verbal de-escalation. If unsuccessful and the patient can cooperate with oral medication, offer oral or sublingual formulations before proceeding to injection — oral dissolving olanzapine and risperidone solution are options. If intramuscular medication is required, the most widely used protocol is intramuscular haloperidol 5 milligrams combined with intramuscular lorazepam 1 to 2 milligrams — decades of clinical experience support its efficacy and safety. Adding diphenhydramine reduces acute dystonia risk in antipsychotic-naive patients.

Intramuscular olanzapine 10 milligrams is an effective alternative with lower extrapyramidal symptom risk than haloperidol. The critical safety rule: intramuscular olanzapine must never be co-administered with intramuscular or intravenous benzodiazepines in the same session — cases of severe respiratory depression and deaths have been reported with this specific combination. This contraindication is absolute regardless of clinical urgency. Intramuscular ziprasidone 10 to 20 milligrams is an option with minimal extrapyramidal symptom risk but requires prior electrocardiogram assessment to confirm absence of QTc prolongation. Inhaled loxapine produces rapid calming (approximately 10 minutes onset) via pulmonary delivery but is restricted to settings where bronchospasm management is available, as it is contraindicated in patients with asthma or chronic obstructive pulmonary disease.

After the acute episode is controlled, monitor respiratory rate and oxygen saturation for at least 1 hour following intramuscular administration. Reassess the underlying psychiatric condition and antipsychotic regimen — recurrent agitation requiring repeated rapid tranquilization may signal inadequate maintenance treatment or treatment resistance requiring systematic escalation.